<DOC>
	<DOC>NCT02509091</DOC>
	<brief_summary>The therapy of bronchoalveolar lavage and local amikacin injection as one of the treatment of bronchiectasis developed in recent years.this study is aim to evaluate the Clinical Efficacy and Safety of Therapy of Bronchoalveolar Lavage and Local Amikacin Injection in Patients with Acute Exacerbation of Bronchiectasis.</brief_summary>
	<brief_title>Therapy of Bronchoalveolar Lavage and Local Amikacin Injection in Patients With Acute Exacerbation of Bronchiectasis</brief_title>
	<detailed_description>The aim of this study was to evaluate the efficacy and safety of The therapy of bronchoalveolar lavage and local amikacin injection through the observation of a large sample of clinical cases. During the observation, study visits will occur at the end of 30days, 60days, 90days.all the participants will be required to check the various efficacy and safety indicators.</detailed_description>
	<mesh_term>Bronchiectasis</mesh_term>
	<mesh_term>Amikacin</mesh_term>
	<criteria>1. Age≥18 years and ≤80 years; 2. Patients with noncystic fibrosis bronchiectasis diagnosed by highresolution CT; 3. Are sensitive to amikacin; 4. Acute exacerbation of bronchiectasis; 5. Capable of the completion of bronchoscopy, alveolar lavage, pulmonary function testing etc; 6. Willing to join in and sign the informed consent form. 1. Active bleeding without control； 2. Receiving nasal or facial surgery recently； 3. With severe cardiopulmonary dysfunction, such as left heart failure, unstable arrhythmia, etc. 4. With other respiratory diseases: such as active pulmonary tuberculosis, nontuberculosis mycobacteria (NTM) pulmonary disease, pulmonary aspergillosis, etc. 5. Be allergic to amikacin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>